Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05336266 · ClinicalTrials.gov registry record · Early Phase 1
A Feasibility Study of Ketorolac Treatment for Cachexia in Patients With Advanced Pancreatic Ductal Adenocarcinoma
A Early Phase 1 study of Pancreatic Cancer and Pancreatic Ductal Adenocarcinoma, sponsored by Andrew Hendifar, MD.
- Active
- Registry status
- Early Phase 1
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT05336266 is a Early Phase 1 study of Pancreatic Cancer and Pancreatic Ductal Adenocarcinoma that is active but no longer recruiting, run by Andrew Hendifar, MD. The registered enrollment target is 28 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05336266, a Early Phase 1 study of Pancreatic Cancer and Pancreatic Ductal Adenocarcinoma, is active but no longer recruiting, sponsored by Andrew Hendifar, MD.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to see if taking ketorolac, a nonsteroidal anti-inflammatory drug (NSAID), is reasonable, safe and can stabilize or increase weight along with quality of life in pancreatic cancer patients.
Conditions Studied
Interventions
- DRUG Ketorolac Tromethamine
Study Locations (1)
California
- Cedars- Sinai Medical Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2022-07-01 |
| Est. Completion | 2026-12-05 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05336266
The ClinicalTrials.gov registry entry for NCT05336266 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (93% lower). The listed sponsor is Andrew Hendifar, MD, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which Ketorolac Tromethamine is the first listed.
NCT05336266 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05336266 about?
NCT05336266 is a clinical study titled "A Feasibility Study of Ketorolac Treatment for Cachexia in Patients With Advanced Pancreatic Ductal Adenocarcinoma". The purpose of this study is to see if taking ketorolac, a nonsteroidal anti-inflammatory drug (NSAID), is reasonable, safe and can stabilize or increase weight along with quality of life in pancreatic cancer patients.
What is the current status of trial NCT05336266?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 28 participants. The study started on 2022-07-01. Estimated completion is 2026-12-05.
What conditions does trial NCT05336266 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Pancreas Cancer.
What interventions are being tested in trial NCT05336266?
The interventions under investigation include: Ketorolac Tromethamine (DRUG).
Who is sponsoring clinical trial NCT05336266?
This trial is sponsored by Andrew Hendifar, MD, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05336266 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
RECRUITING · Early Phase 1
-
Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Pancreatic Cancer
RECRUITING · Early Phase 1
-
Lidocaine Infusion in Pancreatic Cancer
RECRUITING · Early Phase 1
-
Feasibility Study of Oral Ketamine Versus Placebo for the Treatment of Anxiety in Patients With Pancreatic Cancer
RECRUITING · Early Phase 1
-
Imaging Study of 18F-FAC PET Scans to Assess Standard Treatment in People With Pancreatic Cancer
ACTIVE NOT RECRUITING · Early Phase 1
-
Preoperative Rehabilitation During Neoadjuvant Therapy for Pancreatic Cancer
COMPLETED · Early Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.